BOULDER, Colo.--(BUSINESS WIRE)--Jan. 30, 2012--
Array BioPharma Inc. (NASDAQ: ARRY) announced that it has elected Gwen
A. Fyfe, M.D., to its Board of Directors. Dr. Fyfe is an oncology
biotechnology veteran with more than 20 years of drug development
experience.
“We are thrilled to have a person of Gwen’s caliber join the Array
Board. She is an industry leader with an excellent track record of
clinical success,” said Kyle Lefkoff, Executive Chairman. “Gwen’s
expertise and leadership in advancing cancer therapeutics, including
Rituxan®, Herceptin®, Avastin® and
Tarceva®, make her an ideal addition to our Board of
Directors. We look forward to her contributions.”
Dr. Fyfe added, “It’s an exciting time to join the Board of Directors of
Array. The Company’s diverse pipeline of products and its multiple
successful partnerships reflect the quality of Array’s research and
development efforts.”
From 1997 to 2009, Dr. Fyfe held various positions with Genentech, Inc.
(now a member of the Roche Group), including Vice President, Oncology
Development; Vice President, Avastin® Franchise Team; as well
as the honorary title of Senior Staff Scientist. Dr. Fyfe played an
important role in the development of Genentech’s approved oncology
agents including Rituxan®, Herceptin®, Avastin®
and Tarceva®. Dr. Fyfe sat on the development oversight
committee for all of Genentech’s products and participated in the
Research Review Committee that moved products from research into
clinical development. Since leaving Genentech in 2009, Dr. Fyfe has been
a consultant for venture capital firms and for a variety of
biotechnology companies. Dr. Fyfe is a recognized oncology expert in the
broader oncology community and has been an invited member of Institute
of Medicine panels, National Cancer Institute working groups and grant
committees and American Society of Clinical Oncologists oversight
committees. She is a graduate of Washington University School of
Medicine and a board certified pediatric oncologist.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small-molecule
drugs to treat patients afflicted with cancer and inflammatory diseases.
Array has four core proprietary clinical programs: ARRY-614 for
myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for
pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded
clinical programs including two MEK inhibitors in Phase 2: selumetinib
with AstraZeneca and MEK162 with Novartis. For more formation on Array,
please go to www.arraybiopharma.com.
Source: Array BioPharma
Array BioPharma
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com
